A number of other research firms also recently weighed in on OPK. Oppenheimer Holdings Inc. reaffirmed a hold rating on shares of Opko Health in a research note on Thursday, June 16th. Zacks Investment Research downgraded shares of Opko Health from a hold rating to a sell rating in a research note on Friday, July 1st. Standpoint Research raised their target price on shares of Opko Health from $16.00 to $18.00 and gave the company a buy rating in a research note on Tuesday, June 21st. Deutsche Bank AG cut their target price on shares of Opko Health from $11.00 to $10.00 and set a hold rating on the stock in a research note on Thursday, June 16th. Finally, JPMorgan Chase & Co. set a $14.00 target price on shares of Opko Health and gave the company a buy rating in a research note on Tuesday, August 9th. Five research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $13.20.
Opko Health (NYSE:OPK) opened at 9.56 on Monday. The firm has a 50-day moving average of $10.06 and a 200 day moving average of $10.08. Opko Health has a 1-year low of $7.12 and a 1-year high of $11.85. The firm has a market cap of $5.26 billion and a P/E ratio of 40.00.
Opko Health (NYSE:OPK) last posted its quarterly earnings results on Monday, August 8th. The company reported $0.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.03) by $0.05. The company had revenue of $357.10 million for the quarter, compared to analysts’ expectations of $324.11 million. The business’s revenue for the quarter was up 742.2% on a year-over-year basis. During the same period in the prior year, the business earned ($0.09) EPS. On average, analysts predict that Opko Health will post ($0.05) EPS for the current year.
In related news, CEO Phillip Md Et Al Frost acquired 10,000 shares of the firm’s stock in a transaction on Tuesday, August 2nd. The stock was bought at an average cost of $9.88 per share, with a total value of $98,800.00. Following the acquisition, the chief executive officer now directly owns 3,068,951 shares in the company, valued at $30,321,235.88. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
A number of hedge funds and other institutional investors have recently made changes to their positions in OPK. California State Teachers Retirement System raised its position in Opko Health by 6.1% in the second quarter. California State Teachers Retirement System now owns 682,157 shares of the company’s stock valued at $6,371,000 after buying an additional 39,160 shares during the period. Teachers Advisors Inc. raised its position in Opko Health by 3.6% in the first quarter. Teachers Advisors Inc. now owns 325,172 shares of the company’s stock valued at $3,379,000 after buying an additional 11,403 shares during the period. Bank of New York Mellon Corp raised its position in Opko Health by 3.7% in the second quarter. Bank of New York Mellon Corp now owns 1,343,344 shares of the company’s stock valued at $12,547,000 after buying an additional 47,942 shares during the period. BlackRock Group LTD raised its position in Opko Health by 19.1% in the first quarter. BlackRock Group LTD now owns 251,817 shares of the company’s stock valued at $2,616,000 after buying an additional 40,321 shares during the period. Finally, Jaffetilchin Investment Partners LLC raised its position in Opko Health by 1.2% in the second quarter. Jaffetilchin Investment Partners LLC now owns 450,450 shares of the company’s stock valued at $4,207,000 after buying an additional 5,182 shares during the period.
About Opko Health
OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.